Multiple Law Firms Seek Gossamer Investors to Lead Securities Lawsuit

Overview

• Three shareholder‑rights firms issued investor solicitations Wednesday asking Gossamer Bio shareholders to join a securities class action and to move for lead‑plaintiff appointment before the June 1 deadline.
• The complaints say Gossamer made false or misleading statements by concealing problems with its Phase 3 PROSERA trial design and with controls for placebo response at certain testing sites.
• Firms specifically point to unusually strong placebo performance at Latin American sites and allege that those site differences contributed to the trial missing its primary endpoint.
• The actions invoke federal securities claims under Sections 10(b), 20(a) and Rule 10b‑5, but the allegations are unproven and the class has not been certified.
• Who is appointed lead plaintiff and whether a court certifies a class will shape who runs the case, how damages are pursued, and the timetable for any recovery or regulatory review.